Our core competency lies in the strategic orchestration of commercial activities that are pivotal for early-stage drug development and successful market penetration, both in the U.S. and beyond.
Our methodology is distinguished by early engagement in the clinical development process. This proactive approach enables the assimilation of critical insights from payers, providers, and patients into the target medicine profile. The result is a meticulously crafted evidence generation plan and an all-encompassing strategy that ensures the asset’s successful commercialization.
At MIRADOR Global, we do not merely consult; we integrate. Our team of experts, armed with real-world experience in global commercialization, market access, reimbursement, and pricing strategies, becomes an extension of your existing teams. We supplement your internal capabilities with our specialized knowledge, thereby elevating your commercial launch strategy effectiveness and impact.
Mirador Global is the go-to partner for commercial strategy development and execution for emerging biopharma and established pharma emerging brands teams, addressing US, EU4/UK and JP markets
Mirador Global is equipped with proven, proprietary, integrated, client focused solutions, and core product offerings spanning marketing, payer, insights & analytics, strategic planning, and medical affairs
Our consultants have deep expertise in both client and consulting roles, spanning multiple business functions, therapeutic areas and geographies and work collaboratively with clients to deliver high value outcomes.
MIRADOR Global can help you create a global forecast that strategically shapes the future value of your asset at every phase of development. Our epidemiological forecasting methodology centers on the patient. In collaboration with you, we guide you in identifying the patient need and the pathway to reimbursement which leads to your asset’s financial potential.
A well-built pharmaceutical forecast does more than produce a number. It aligns teams, tests assumptions, and shapes the strategic decisions behind a product launch. This series walks through how to make forecasting work as a strategic asset, from establishing the right patient funnel through choosing the methods that fit your asset’s stage.
Start with Forecasting as a Strategic Tool, which shows how a robust patient/opportunity funnel and cross-functional input turn a forecast into a driver of strategic discussion and a way to answer the questions investors ask. Then Forecasting Pre-Launch Pharmaceutical Products focuses on Phase 2 through Phase 3 assets, covering how to match purpose, audience, and level of detail to build a defensible model. Finally, Approaches to Pharmaceutical Demand Forecasting compares four core methods, top-down analogs, bottom-up epidemiology, statistical trend, and prescriber behavior, with the pros, cons, and right moment for each.